Medincell SA
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is… Read more
Medincell SA (MEDCL) - Total Liabilities
Latest total liabilities as of September 2025: €105.21 Million EUR
Based on the latest financial reports, Medincell SA (MEDCL) has total liabilities worth €105.21 Million EUR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Medincell SA - Total Liabilities Trend (2016–2025)
This chart illustrates how Medincell SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Medincell SA Competitors by Total Liabilities
The table below lists competitors of Medincell SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Molson Coors Canada Inc
TO:TPX-B
|
Canada | CA$12.20 Billion |
|
Shaanxi Heimao Coking Co Ltd
SHG:601015
|
China | CN¥11.98 Billion |
|
Shenzhen Lihexing Co. Ltd.
SHE:301013
|
China | CN¥777.93 Million |
|
FirstSun Capital Bancorp Common Stock
OTCQX:FSUN
|
USA | $7.37 Billion |
|
Arbutus Biopharma Corp
NASDAQ:ABUS
|
USA | $20.31 Million |
|
Shandong Jincheng Pharmaceutical and Chemical Co Ltd
SHE:300233
|
China | CN¥1.42 Billion |
|
Cosonic Intelligent Tech Co Ltd
SHE:300793
|
China | CN¥1.41 Billion |
Liability Composition Analysis (2016–2025)
This chart breaks down Medincell SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Medincell SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Medincell SA (2016–2025)
The table below shows the annual total liabilities of Medincell SA from 2016 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | €106.82 Million | +37.35% |
| 2024-03-31 | €77.77 Million | +8.57% |
| 2023-03-31 | €71.63 Million | +24.20% |
| 2022-03-31 | €57.67 Million | +5.46% |
| 2021-03-31 | €54.69 Million | +26.41% |
| 2020-03-31 | €43.27 Million | +36.31% |
| 2019-03-31 | €31.74 Million | -14.45% |
| 2018-03-31 | €37.10 Million | +45.20% |
| 2017-03-31 | €25.55 Million | +159.47% |
| 2016-03-31 | €9.85 Million | -- |